Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences
Open Access
- 6 August 2009
- journal article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 7 (1), 69
- https://doi.org/10.1186/1479-5876-7-69
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The H19 Non-Coding RNA Is Essential for Human Tumor GrowthPLOS ONE, 2007
- Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic propertyInternational Journal of Gynecologic Cancer, 2006
- Regulatory sequences of H19 and IGF2 genes in DNA‐based therapy of colorectal rat liver metastasesThe Journal of Gene Medicine, 2004
- Possible physiological role of H19 RNAMolecular Carcinogenesis, 2002
- The expression of the H19 gene and its function in human bladder carcinoma cell linesFEBS Letters, 1999
- Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinomaMolecular Pathology, 1998
- The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?Oncogene, 1997
- The expression of the imprinted H19 and IGF‐2 genes in human bladder carcinomaFEBS Letters, 1995
- Endometrioid carcinoma of the ovary presenting with an enlarged inguinal lymph node without evidence of abdominal carcinomatosisGynecologic Oncology, 1992
- Expression of Diphtheria Toxin A-Chain in Mature B-Cells: A Potential Approach to Therapy of B-Lymphoid MalignancyLeukemia & Lymphoma, 1992